The Role of Targeted Osmotic Lysis in the Treatment of Advanced Carcinoma in Companion Animals: A Case Series

Author:

Gould Harry J.12ORCID,Edenfield Samantha3ORCID,Miller Paige R.2ORCID,Sherman Kelly Jean3ORCID,Melius Brian4ORCID,Whitney Alissa5ORCID,Hunter Robert P.6ORCID,Del Piero Fabio7,Tracey Dennis28ORCID,Paul Dennis23ORCID

Affiliation:

1. Department of Neurology, Louisiana State University Health Sciences Center, New Orleans, LA, USA

2. Oleander Medical Technologies, Baton Rouge and New Orleans, LA, USA

3. Department of Pharmacology and Experimental Therapeutics, USA

4. Metairie Small Animal Hospital, Metairie, LA, USA

5. Monroe Street Animal Hospital, Mandeville, LA, USA

6. One Medicine Consulting, Olathe, KS, USA

7. Department of Pathobiological Sciences and Louisiana Animal Disease Diagnostic Laboratory (LADDL), Louisiana State University School of Veterinary Medicine, Baton Rouge, LA, USA

8. Big Easy Medical, 6818 Memphis St New Orleans, LA 70124, USA

Abstract

Background. Targeted osmotic lysis (TOL) is a novel technology that involves concomitant stimulation of voltage-gated sodium channels (VGSCs) and the pharmacological blockade of Na+, K+-ATPase causing lysis of highly malignant cancer cells. Hypothesis/Objectives. TOL offers an option for treating advanced carcinomas in companion animals. Animals. Two cats and 2 dogs that presented to veterinary hospitals for evaluation and treatment of one of several forms of carcinoma. Methods. Digoxin was administered to achieve steady-state, therapeutic concentrations. The animals were then exposed to pulsed electric field stimulation. Pre- and posttreatment assessments of tumor size and quality of life were compared. The treatment frequency and survivability varied, based on the patient’s premorbid functioning and response to treatment. Results. Regardless of cancer type, TOL consistently increased survival beyond expected, often improving, but without compromising of quality of life. Conclusions and Clinical Importance. TOL warrants consideration as an option for managing advanced carcinomas.

Funder

Louisiana Board of Regents Fellowship for Graduate Training in Integrative Pharmacological Sciences

Publisher

Hindawi Limited

Subject

General Veterinary

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3